Normal Face Detection Over a Range of Luminance Contrasts in Adolescents With Autism Spectrum Disorder.

Face recognition is impaired in autism spectrum disorders (ASDs), but the reason for this remains unclear. One possibility is that impairments in the ability to visually detect faces might be a factor. As a preliminary study in this vein, we measured face detection ability as a function of visual contrast level in 13 individuals with ASD, aged 13-18, and 18 neurotypical controls (NCs) in the same age range. We also measured contrast sensitivity, using sinusoidal grating stimuli, as a control task. Individuals with ASD did not differ from controls in face detection (p > 0.9) or contrast detection (p > 0.2) ability. Performance on contrast and face detection was significantly correlated in ASD but not in NC. Results suggest that the ability to visually detect faces is not altered in ASD overall, but that alterations in basic visual processing may affect face detection ability in some individuals with ASD.

Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer's disease.

BACKGROUND: Over the past decade, visual short-term memory (VSTM) binding tests have been shown to be one of the most sensitive behavioral indicators of Alzheimer's disease (AD), especially when they require the binding of multiple features (e.g., color and shape). Recently, it has become possible to directly measure amyloid and tau levels in vivo via positron emission tomography (PET). To this point, these behavioral and neurochemical markers have not been compared in humans with AD or at risk for it. METHODS: In a cross-sectional study, we compared VSTM performance to tau and amyloid concentrations, measured by PET, in individuals certain to develop AD by virtue of their inheritance of the presenilin-1 E280A mutation. These included 21 clinically unimpaired subjects and 7 subjects with early mild cognitive impairment (MCI), as well as 30 family members who were not carriers of the mutation. RESULTS: We found that VSTM performance correlated strongly with tau in entorhinal cortex and inferior temporal lobe, and also with amyloid when examining asymptomatic carriers only. The condition requiring binding was not preferentially linked to tau-in fact, the non-binding "shape only" condition showed a stronger relationship. CONCLUSIONS: The results confirm VSTM's status as an early marker of AD pathology and raise interesting questions as to the course of binding-specific versus non-binding aspects of VSTM in early AD.

Chemiluminescent aptasensor capable of rapidly quantifying Escherichia Coli O157:H7.

Cost-effective and easy-to-use biosensor was developed for the rapid quantification and monitoring of Escherichia (E.) Coli O157:H7 in sample using E. Coli O157:H7 aptamer, graphene oxide (GO)/iron nanocomposites, and guanine chemiluminescence detection. E. Coli O157:H7 aptamer-conjugated 6-carboxyfluorescein (6-FAM) with excellent specificity captured E. Coli O157:H7 in a sample when the mixture was incubated for 1h at 37°C. Free E. Coli O157:H7 aptamers remaining in sample after the incubation were removed with GO/iron nanocomposites based on the principle of π-π stacking interaction between free aptamer and GO/iron nanocomposites. Then, E. Coli O157:H7 bound with aptamer-conjugated 6-FAM in sample emitted strong light when guanine chemiluminescent reagents (e.g., 3,4,5-trimethoxylphenylglyoxal hydrate, Tetra-n-propylammonium hydroxide) were added in the sample. The strength of light emitted in guanine chemiluminescence reaction was proportionally enhanced with the increase of E. Coli O157:H7 concentration. The limit of detection (LOD) of biosensor capable of quantifying E. Coli O157:H7 with good accuracy, precision, and reproducibility was as low as 4.5×10(3)cfu/ml. We expect that the rapid analytical system can be applied in the field of food safety as well as public health.